[ad_1]
Michael Chancley, communications director, PrEP4All, and PrEP user.
AIDSVu.org: “Local Data: Louisiana.”
CDC.gov: “HIV and Women: HIV Diagnoses,” “HIV Surveillance Data Tables. Table 3a,” “PrEP Effectiveness,”
FDA.gov: “FDA Approves First Injectable Treatment for HIV Pre-Exposure Prophylaxis,” Dec. 20, 2021, “FDA approves second drug to prevention HIV infection as part of ongoing efforts to end the HIV epidemic,” Oct. 2, 2019, “FDA approves Cabenuva and Vocabria for Treatment of HIV-1 Infection.”
Dawn K. Smith, MD, epidemiologist and medical officer, CDC.
HIV.gov: “FDA approves first drug for reducing the risk of sexually acquired HIV infection,” July 16, 2021.
Kimberly Smith, MD, senior vice president and head of research and development, ViiV Healthcare.
Maggie Czarnogorski, head of innovation and implementation science, ViiV Healthcare.
Dora Martinez, MD, medical director, Westbrook Clinic, McAllen, TX.
DataUSA.io: “Cameron County, TX.”
PleasePrEPMe.org: “Harlingen, TX,” “McAllen, TX,” “Brownsville, TX.”
AIDSVu.org: “Cameron County, TX.”
Audrey Abernathy, head of communications and external affairs, ViiV Healthcare.
Sean Bland, JD, senior associate, Infectious Diseases Initiative, O’Neill Institute for National and Global Health Law, Georgetown Law.
AmfAR.org: “Long-Acting HIV Treatment and Prevention Are Coming: Preparing for Potential Game Changers.”
Melinda Stubbee, spokesperson, ViiV Healthcare
JAMA Network Open: “Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence among US adults in an integrated health care system.”
Conference on Retroviruses and Opportunistic Infections: “PrEP Use and Referral: Black Partners of People With HIV in Partner Services, 2019.”
AIDS and Behavior: “The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): Assumptions about sexual risk compensation and implications for access.”
[ad_2]
Source link
